The Antibody Drug Conjugates Market is appreciated to demonstrate a substantial upswing of a CAGR of 12.9% during the forecasted period of 2023 to 2030. The Antibody Drug Conjugates Market is set to be valued at USD 3,198 billion in 2023 and is estimated to display a significant improvement of USD 7475.74 billion by 2030.
Global Antibody Drug Conjugate Market- INTRODUCTION
The Antibody-Drug Conjugates (ADCs) Market is comprised of sales of Antibody-Drug Conjugates (ADCs). Antibody-drug conjugates (ADCs) are complexly manufactured therapeutics that consist of monoclonal antibodies, directed towards the tumour-associated antigens, which highly influence cytotoxic agents that are attached using chemical linkers.
The hurdles involved in the manufacturing of ADC act as restrictions on the antibody-drug conjugate market. ADC manufacturing requires a high capital investment and extensive specialized training for operators.
ADC development is a complicated process because it bees in a need of optimization of additional processing steps which are unpresented in conventional monoclonal antibody manufacturing. For example, the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates should be made in aseptic environments and the working person should be protected from the highly toxic drug compounds, which may cause operational problems and complications.
Manufacturers of antibody-drug conjugates are vigorously collaborating with other companies to share technology, product knowledge, resources and expand the business. In March 2019, AstraZeneca signed an agreement with commercialization collaboration and Global Development with Daiichi Sankyo Company for becoming the sole manufacturer of the antibody-drug conjugate Trastuzumab Deruxtecan (DS-8201).
In April 2019, Shanghai Microgen agreed with the Netherlands based Synaffix to use its tools for manufacturing antibody-drug conjugates. As per the deal, Microgen licenced two platforms from Synaffix which will boost the product growth.
Global Antibody Drug Conjugate Market- Overview
Antibody Drug Conjugates Market are thoroughly effective Biopharmaceutical medications designed as a targeted therapy for cancer treatment. ADCs are outlined to abolish cancer cells without causing any harm to the normal cells. This is a great advantage of ADC’s, how the unharmed healthy cells make patients recover quicker.
There is an increase in the commonness of cancer worldwide due to an unhealthy urban lifestyle and the urge to consume tobacco and alcohol proves to be a risk factor in the growing cases of cancer.
According to National Cancer Institute, “people or patients living beyond the predicted time of diagnosed cancer will approximately reach 19 Million by 2024.”
Demand for quality cancer treatment and cost-effectiveness is also expected to hike the ADC’s market growth rate.
Request a sample copy of Antibody Drug Conjugates Market: https://wemarketresearch.com/sample-request/antibody-drug-conjugates-market/132/
Global Antibody Drug Conjugates Market- Segmental Analysis
Market has been segmented into sections namely, Drugs, Mechanism of Action, Application, Technology, End User
Key Players:-
- AbbVie Inc.
- ADC Therapeutics
- Agensys Inc.
- Antikor
- Astellas Pharma, ADC Therapeutics
- Bayer AG
- Celldex Therapeutics
- Concortis Biotherapeutics
- Daiichi Sankyo Company Ltd.
- Genentech
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Heidelberg Pharma
- ImmunoGen Inc.
- Immunomedics Inc.
- Mersana Therapeutics
- Millennium Pharmaceuticals
- Oxford Biotherapeutics.
- Pfizer Inc.
- Progenics Pharmaceuticals
- Roche Holding Ag
- Seagen, Inc.
- Seattle Genetics Inc.
- Synthon
- Takeda Pharmaceutical Company Limited
Antibody Drug Conjugates Market based on Drugs: Analysis
- Kadcyla
- Adcetris
- Besponsa
- Lumoxiti
- Mylotarg
- Others
Kadcyla was one of the approved drugs by US and Europe for collateral treatment for early patients of HER2-positive breast cancer. The approval of Kadcyla for early-stage treatment is expected to boost the market.
Antibody Drug Conjugates Market by Mechanism of Action: Analysis
- HER2 Antibodies
- CD30 Antibodies
- Others
Antibody Drug Conjugates Market by Application: Analysis
- Lymphoma
- Breast Cancer
- Blood Cancer
- Skin cancer
- Brain Tumor
- Ovary Cancer
- Brain Cancer
- Urothelial & Bladder Cancer
- Other Types of Cancer
Among the application segment the blood cancer segment is anticipated to nurture at a CAGR of 19.4% during the anticipated term. This is attributable to rising incidences of cancerous diseases and approval for ADC’s.
Antibody Drug Conjugates Market by Technology: Analysis
- InnunoGen technology
- Seattle Genetics technology
- Immunomedics technology
- Others
Antibody Drug Conjugates Market by End User: Analysis
On the basis of end use the global antibody drug conjugates market has been segmented into Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology, Retail Pharmacies, Biopharmaceutical Companies and others. Antibody drug conjugates are used in cancer cell therapy and for research and clinical trials.
Purchase Global Antibody Drug Conjugates Market Research Report:- https://wemarketresearch.com/purchase/antibody-drug-conjugates-market/132/?license=single
Table of Contents
- Global Antibody Drug Conjugates Market Introduction and Market Overview
- Global Antibody Drug Conjugates Market – Executive Summary
- Antibody Drug Conjugates Market Trends, Outlook, and Factors Analysis
- Global Antibody Drug Conjugates Market: Estimates & Historic Trend Analysis (2018 to 2021)
- Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Deployment
- Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Component
- Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Content Type
- Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by End Use
- Global Antibody Drug Conjugates Market Analysis and Forecast, by Region
- North America Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
- Europe Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
- Asia Pacific Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
- Middle East & Africa Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
- Latin America Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
- Competitive Landscape
- Company Profiles
- Assumptions and Research Methodology
- Conclusions and Recommendations
Frequently Asked Question About This Report
- How are antibody-drug conjugates made?
- What are tumour-associated antigens?
- What is the usage of antibody-drug conjugates?
- What is the expected compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?
- Which segment held the largest antibody-drug conjugate market share?
- What was the Antibody-drug Conjugates market size in 2020?
- What is the percentage growth rate of antibody-drug conjugates market?
- How many antibody-drug conjugates are approved?
About We Market Research
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
We Market Research
Phone: +1(929)-450-2887
Email: sales@wemarketresearch.com
